Moreover, F292A CAR T in vivo efficacy was superior to the scFv-based R6.5 CAR despite an over 1,000-fold lower affinity to ICAM-1 (10 nM vs. 20 μM), as evidenced by a faster rate of tumor clearance and durable suppression of tumor relapse (Fig. 4a). The gene discussed is ICAM1; the disease is neoplasm.